News

Filter

Current filters:

Asia-PacificBiosimilars

1 to 9 of 11 results

JHL Biotech’s new $35 million financing will fund biosimilars

JHL Biotech’s new $35 million financing will fund biosimilars

22-06-2014

Taiwan biopharma company JHL Biotech say it has closed a Series B financing round of $35 million, led…

Asia-PacificBiosimilarsBiotechnologyFinancialJHL BiotechProductionResearch

Fast growth forecast for South Korean pharma market

Fast growth forecast for South Korean pharma market

02-04-2014

South Korea's pharmaceuticals market was valued at $20 billion in 2012, growing from $14.5 billion in…

Asia-PacificBiosimilarsBiotechnologyMarkets & MarketingPricingResearch

India now making moves into pharma innovation

India now making moves into pharma innovation

03-03-2014

In what must be seen as a significant change in focus, India is now seeing a surge of innovative research…

Asia-PacificBiosimilarsIndiaMarkets & MarketingPharmaceuticalResearch

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP

10-02-2014

Swiss pharma major Roche’s Indian subsidiary has sued Bangalore-based Biocon and US generics firm Mylan…

Asia-PacificBioconBiosimilarsCanmabHerceptinHertrazIndiaLegalMylan LaboratoriesOncologyPatentsPharmaceuticalRegulationRoche

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

Celltrion’s trastuzumab biosimilar, Herzuma, approved in South Korea

16-01-2014

South Korean biopharmaceutical firm Celltrion has received approval for its cancer treatment biosimilar…

Asia-PacificBiosimilarsCellTrionGenericsHerceptinHerzumaOncologyRegulationRoche

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

31-12-2013

China’s Walvax Biotech has revealed it plans to acquire a controlling 64% equity stake in Shanghai’s…

Asia-PacificBiosimilarsBiotechnologyChinaMergers & AcquisitionsOncology

Lack of familiarity with biosimilars among South Korean oncologists

Lack of familiarity with biosimilars among South Korean oncologists

16-12-2013

South Korean oncologists are significantly less familiar with biosimilars than oncologists surveyed in…

Asia-PacificBiosimilarsChinaGenericsOncology

1 to 9 of 11 results

COMPANY SPOTLIGHT

Menarini

Back to top